Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1193)	7/8/2005 4:49:25 PM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

SGEN Has been doing OK in spite of announcing Wednesday that it was dropping development of its SGN-15 for lung Ca because results while "encouraging," were not impressive enough to justify a PIII. Apparently, it was more important its announcement on May 3 that it had received a patent relating to its antibody-drug ADC technology. (By linking cytotoxic drug payloads to monoclonal antibodies, ADCs can increase the potential effect of antibodies.) SGEN uses its ADC tech in its SGN-35 and SGN-75 and it licenses it to several biotech & pharma companies (DNA,Bayer,CRGN and MEDI) The stock traded today above its May 6 H of 5.95 and if it can close above its Feb.7 H of 6.10 it seems it could get to test its Dec.14-Dec.15 double top at 7.05 <g> bigcharts.marketwatch.com Bernard